MedTrace Logo

SPP100 Dose Finding Study in Japan

NCT00311012 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 445

Last updated 2011-11-08

No results posted yet for this study

Summary

This study will evaluate the efficacy of SPP100 in lowering blood pressure in patients with essential hypertension.

Conditions

Interventions

DRUG

Aliskiren

Sponsors & Collaborators

Principal Investigators

  • Novartis Pharmaceuticals, Japan · Novartis Pharmaceuticals, Japan

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
20 Years
Max Age
80 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2004-08-31
Primary Completion
2005-03-31
Completion
2005-03-31

Countries

  • Japan

Study Locations

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00311012 on ClinicalTrials.gov